Mr. Kazimi is the Chairman of the Board of Directors and Chief Executive Officer of Cumberland Pharmaceuticals Inc., which he founded in 1999. His career includes over 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company’s other commercial products. He was responsible for Cumberland’s initial public offering and listing on the NASDAQ stock exchange. 

Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies – a joint initiative with Vanderbilt University and the state of Tennessee – designed to support the development of early-stage life sciences programs and companies. 

Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company’s growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions. 

He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society, the Owen Advisory Council at the Vanderbilt University Business School, and the Visiting Committee at the Loyola University New Orleans College of Business. 

He previously served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has twice been sold to private equity investors. Mr. Kazimi holds an M.B.A. from the Vanderbilt University Owen Graduate School of Management and a B.S. from the University of Notre Dame.

The board believes that Mr. Kazimi brings strategic insight, leadership, and a history of successful execution to the Company along with a wealth of experience in both the biopharmaceutical industry and the development of emerging companies.